Last reviewed · How we verify
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.
Details
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 47 |
| Start date | Fri Nov 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Nov 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- CD30+ Peripheral T-cell Lymphoma
Interventions
- Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
- Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)
- Maintenance therapy-chidamide
Countries
China